Charak B S, Banavali S D, Iyer R S, Saikia T K, Gopal R, Advani S H
Department of Medical Oncology, Tata Memorial Hospital, Bombay, India.
Indian J Cancer. 1991 Jun;28(2):108-13.
Twenty-five patients with acute nonlymphoblastic leukemia undergoing 41 cycles of chemotherapy with daunorubicin/cytosine arabinoside (ara-C) or with etoposide/ara-C received metoclopramide (MCP; 0.5 mg/kg 6 hourly i.v.) or MCP (same dose) plus oral lorazepam (1 mg/d) during and 24 hours following the chemotherapy as antiemetic medication. Control of vomiting was achieved is 55% (complete 5%, partial 50%) of the patients receiving MCP alone and in 100 percent (complete 76.1%; partial 23.8%) of those receiving MCP plus lorazepam (p less than 0.001). Eighteen of the 21 patients (85.7%) receiving MCP plus lorazepam opted for the same antiemetic regimen as compared to six of the 20 (30%) receiving MCP alone (p less than 0.01). One patient in each group developed mild sedation during the treatment. It is concluded that oral lorazepam is an effective and safe adjuvant to MCP for the control of vomiting during cancer chemotherapy.
25例急性非淋巴细胞白血病患者接受了41个周期的柔红霉素/阿糖胞苷（ara-C）或依托泊苷/阿糖胞苷化疗，在化疗期间及化疗后24小时接受胃复安（MCP；0.5mg/kg，每6小时静脉注射一次）或胃复安（相同剂量）加口服劳拉西泮（1mg/d）作为止吐药物。单独接受胃复安治疗的患者中，55%（完全控制5%，部分控制50%）实现了呕吐控制，而接受胃复安加劳拉西泮治疗的患者中，100%（完全控制76.1%；部分控制23.8%）实现了呕吐控制（p<0.001）。接受胃复安加劳拉西泮治疗的21例患者中有18例（85.7%）选择了相同的止吐方案，而单独接受胃复安治疗的20例患者中有6例（30%）选择了相同的止吐方案（p<0.01）。每组各有1例患者在治疗期间出现轻度镇静。结论是，口服劳拉西泮是胃复安控制癌症化疗期间呕吐的一种有效且安全的辅助药物。
